Date: 2011-06-09
Type of information: Licensing agreement
Compound: Isconova’s adjuvant Matrix M™
Company: Isconova (Sweden) Crucell (J&J subsidiary - the Netherlands USA)
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement: licensing
Action mechanism:
Disease: HIIV, malaria
Details: Isconova has entered into a new license agreement with Crucell N.V.. The agreement grants Crucell the license to use Isconova’s adjuvant Matrix M™ in HIV and malaria vaccines. An existing agreement between Isconova and Crucell already granted Crucell the right to use Isconova’s Matrix M™ in influenza vaccines.
Financial terms:
Latest news:
